{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:43:28Z","timestamp":1782737008239,"version":"3.54.5"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Small cell carcinoma (SCC)\/neuroendocrine prostate cancer (NEPC) is a rare and highly aggressive subtype of prostate cancer associated with an AR(androgen receptor)-null phenotype and visceral metastases. This study presents a 44-year-old man originally diagnosed with metastatic hormone-sensitive prostatic adenocarcinoma. After 6-month androgen deprivation therapy (ADT) combined with docetaxel, the patient developed paraplegia. Laminectomy was performed, and a thoracic vertebral biopsy revealed neuroendocrine differentiation and mixed adenocarcinoma. The patient developed liver metastases and experienced stable disease for 4 months following etoposide combined with cisplatin and pembrolizumab. Seminal vesicle biopsy after chemotherapy revealed small-cell cancer. The prostate biopsy specimen also indicated pure SCC. We witnessed the dynamic evolution from pure adenocarcinoma to fully differentiated SCC, leading to obstruction and death. In addition, whole-exome sequencing was performed on both biopsy specimens of the thoracic vertebra at the beginning of castration resistance and that of seminal vesicle after multiple lines of treatment failure. Utilizing phylogenetic reconstruction, we observed that both samples shared a common ancestor clone harboring aberrations in the <jats:italic>TP53<\/jats:italic>, <jats:italic>RB1<\/jats:italic>, and <jats:italic>NF2<\/jats:italic> genes. We also discovered that driver events in the private subclones of both samples, such as alterations in <jats:italic>CDC27<\/jats:italic> and <jats:italic>RUNX1<\/jats:italic>, might have played a significant role in tumor progression or even neuroendocrine differentiation. Tumor biopsy and IHC assessment must be repeated at different stages of progression, because of intrapatient spatial and temporal heterogeneity of adenocarcinoma <jats:italic>versus<\/jats:italic> SCC\/NEPC. Although, typical treatments including ADT, docetaxel, etoposide, cisplatin, and pembrolizumab provided temporary response, the patient still had a poor prognosis.<\/jats:p>","DOI":"10.3389\/fonc.2021.732071","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T18:00:07Z","timestamp":1632765607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Systemic Treatment and Serial Genomic Sequencing of Metastatic Prostate Adenocarcinoma Progressing to Small Cell Carcinoma"],"prefix":"10.3389","volume":"11","author":[{"given":"XiaoJun","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijun","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The Global Burden of Cancer 2013","volume":"1","author":"Fitzmaurice","year":"2015","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-Institutional Prospective Study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.5166","article-title":"Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer","volume":"30","author":"Beltran","year":"2012","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0137","article-title":"The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-1101","article-title":"Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity","volume":"17","author":"Aggarwal","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN Guidelines Insights: Prostate Cancer, Version 1.2021","volume":"19","author":"Schaeffer","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.urology.2006.02.002","article-title":"Neuroendocrine Differentiation in Prostate Cancer","volume":"68","author":"Shariff","year":"2006","journal-title":"Urology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2883","article-title":"PyClone: Statistical Inference of Clonal Population Structure in Cancer","volume":"11","author":"Roth","year":"2014","journal-title":"Nat Methods"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22537","article-title":"A Prolonged Response to Platinum-Based Therapy in a Patient With Metastatic Urothelial Carcinoma Harboring a Single Rearranged and Truncated NF2 Gene","volume":"57","author":"Achkar","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2135-x","article-title":"A Genomic and Epigenomic Atlas of Prostate Cancer in Asian Populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12935-021-01860-9","article-title":"The Importance of CDC27 in Cancer: Molecular Pathology and Clinical Aspects","volume":"21","author":"Kazemi-Sefat","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20160632","article-title":"RUNX Transcription Factors at the Interface of Stem Cells and Cancer","volume":"474","author":"Deltcheva","year":"2017","journal-title":"Biochem J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent Clonal Evolution of Castration-Resistant Neuroendocrine Prostate Cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4053","article-title":"Substantial Interindividual and Limited Intraindividual Genomic Diversity Among Tumors From Men With Metastatic Prostate Cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat5749","article-title":"Reprogramming Normal Human Epithelial Tissues to a Common, Lethal Neuroendocrine Cancer Lineage","volume":"362","author":"Park","year":"2018","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.21","article-title":"Small Cell Carcinoma of the Prostate","volume":"11","author":"Nadal","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discovery"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euo.2020.11.011","article-title":"Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer","volume":"4","author":"Loeb","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized Phase II Study Evaluating Akt Blockade With Ipatasertib, in Combination With Abiraterone, in Patients With Metastatic Prostate Cancer With and Without PTEN Loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11523-016-0453-6","article-title":"mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review","volume":"12","author":"Statz","year":"2017","journal-title":"Target Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S264347","article-title":"Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review","volume":"13","author":"Wu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-015-0204-7","article-title":"Comprehensive Serial Molecular Profiling of an \"N of 1\" Exceptional non-Responder With Metastatic Prostate Cancer Progressing to Small Cell Carcinoma on Treatment","volume":"8","author":"Kadakia","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00060","article-title":"The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression","volume":"4","author":"Terry","year":"2014","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s42003-020-01476-1","article-title":"Single-Cell Analysis Supports a Luminal-Neuroendocrine Transdifferentiation in Human Prostate Cancer","volume":"3","author":"Dong","year":"2020","journal-title":"Commun Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive Genomic Profiles of Small Cell Lung Cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.732071\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T18:00:11Z","timestamp":1632765611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.732071\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":28,"alternative-id":["10.3389\/fonc.2021.732071"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.732071","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"article-number":"732071"}}